

ISSUE DATE July 25, 2014	EFFECTIVE DATE July 22, 2014	NUMBER *See below
SUBJECT Prior Authorization of Hereditary Angioedema (HAE) Agents - Pharmacy Services		BY  Vincent D. Gordon, Deputy Secretary Office of Medical Assistance Programs

PURPOSE:

The purpose of this bulletin is to:

1. Inform providers about new requirements for prior authorization of all Hereditary Angioedema (HAE) Agents.
2. Issue handbook pages that include instructions on how to request prior authorization of prescriptions for HAE Agents, including the type of medical information needed to evaluate requests for medical necessity.

SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program and providing services in the fee-for-service (FFS) delivery system, including pharmacy services to residents of long term care facilities.

BACKGROUND:

The Department of Public Welfare's (Department) Pharmacy and Therapeutics (P&T) Committee meets semi-annually to review published peer-reviewed clinical literature and make recommendations relating to new drugs in therapeutic classes already included in the Preferred Drug List (PDL), changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred, new quantity limits, and new classes of drugs to be added to or deleted from the PDL. The P&T Committee also recommends new guidelines or modifications to existing guidelines to evaluate requests for prior authorization of prescriptions for medical necessity.

*01-14-32	09-14-27	27-14-25	33-14-26
02-14-24	11-14-24	30-14-24	
03-14-27	14-14-24	31-14-30	
08-14-28	24-14-24	32-14-24	

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
<http://www.dpw.state.pa.us/provider/healthcaremedicalassistance/index.htm>

DISCUSSION:

During the May 28, 2014 meeting, the P&T Committee recommended adding the HAE Agents class of drugs to the Department's Preferred Drug List (PDL). Because treatment selection will depend upon contraindications, adverse events, risk factors for adverse effects, tolerance and response to intervention, the Committee recommended prior authorization of both preferred and non-preferred HAE Agents for treatment of this rare disorder. The P&T Committee also recommended guidelines to determine medical necessity. The requirement for prior authorization and the guidelines to determine medical necessity were subject to public review and comment, and subsequently approved for implementation by the Department. The requirements for prior authorization and clinical review guidelines to determine the medical necessity of HAE Agents are included in the attached updated provider handbook pages.

PROCEDURE:

The procedures for prescribers to request prior authorization of HAE Agents are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapters related to HAE Agents) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization.

ATTACHMENTS:

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

SECTION II
Hereditary Angioedema (HAE) Agents